

San Francisco

Spring Group Meeting

SPECIALS

Genitourinary Committee

Genitourinary Committee

Leadership

Chair: Seth P. Lerner, MD
 Vice-Chair: Daniel P. Petrylak, MD
 Chair Emeritus: Ian M. Thompson, Jr., MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Sam Callis, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: David J. McConkey, PhD (GU Chair)
 Joshua J. Meeks, MD, PhD
 Roger Li, MD (Bladder)
 Amir Goldkorn, MD (Prostate)
 Sumanta “Monty” K. Pal, MD (Renal)
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Hiram Shaish, MD
 John D. Hazle, PhD
 Immunotherapeutics: Shuchi Gulati, MD (Medical Onc)
 Robert Svatek, MD (Urologic Onc)
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Early Therapeutics: Parminder Singh, MD
 Bladder Organ Site Chairs: Siamak Daneshmand, MD (Localized)
 Thomas W. Flaig, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 Tanya B. Dorff, MD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)

Designates

Cancer Control: Clara Hwang, MD
 Sarah P. Psutka, MD, MSC
 Digital Engagement: Neema Navai, MD
 NCORP: Scott Edward Delacroix, Jr., MD
 Helen Heng-Shan Moon, MD
 Veterans Affairs: Michael M. Goodman, MD
 Data Coordinators: Laura Wells, BA
 Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals:
 CRAs: Abigail L. Cornette, MS
 Nurse: Gary Lee Duvall, RN

Patient Advocates: Darrell Nakagawa (Bladder)
 Tony Crispino (Emeritus, Prostate)
 Lee Henry Moultrie (Prostate)
 Laura B. Esfeller, MA (Renal)
 Pharmaceutical Science: Joyce Lee, PharmD
 Protocol Project Manager: Megan Keim
 Clinical Trials Program Manager: Mariah Norman, MS

Time/Location

Saturday, May 3, 2025 9:30 a.m. - 11:30 a.m.
 Room: Grand Ballroom A (Street Level)

Agenda

9:30 - 9:45 am: Chair’s Welcome and Opening Remarks - Seth Lerner
 9:45 - 10:10 am: Cancer Control - Clara Hwang and Sarah Psutka
 10:10 - 11:30 am: Review of open approved trials - all organ site chairs
 Renal – Brian Shuch and Ulka Vaishampayan
 Bladder – Sia Daneshmand and Tom Flaig
 Prostate – Dan Lin and Tanya Dorff

Cancer Control

Liaison: Drs. Clara Hwang and Sarah Psutka

Active Studies

S1600, “A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

S1823, “A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors”, PI: Craig Nichols– Activated 6/1/2020 GU Champions: Thomas Frye & Anishka D’Souza

S1931 (Companion Study), “Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer.” PI: Cristiane Bergerot.

S1937 (Companion Study), “Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

Genitourinary Committee

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, "Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)." Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

Concepts in Development

S2419, "Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]." Drs. P. Barata and U. Vaishampayan. GUSC approval received 12/10/24. RaPID call scheduled 3/6/25.

Active Studies

S2200, "A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)" Drs. B. Maughan and S. Pal. Activated 9/19/22.

CTSU/AREN1721, "A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups." Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

CTSU/A031704, "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]." Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

CTSU/A031801, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19.

CTSU/A031901, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20.

Closed Studies

S1500, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005],

Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

S0931, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

CTSU/E2810, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

Priority Study

S1937, "A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy." Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24. Revision #4 had Sacituzumab govitecan removed as a treatment option on 2/3/25.

Concepts in Development

S2427, "Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (BRIGHT)." Dr. L. Ballas. PRC call occurred 1/29/25. Pending first submission to CTEP early March 2025.

Active Studies

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19.

Genitourinary Committee

Step 1 accrual closed 3/1/24. Revision #10 submission to CTEP by end of February 2025.

CTSU/A031701, "A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations." Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, "Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

CTSU/EA8185, "Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)." Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

CTSU/EA8192, "A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy" Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

Closed Studies

S1011, "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17. Listed as FDAAA/IRB Completed on 1/8/25.

S1602, "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

S1605, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

S2011, "Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma." Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23.

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S2210, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14/23.

Concepts in Development

None

Active Studies

S2312, "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Activated 9/3/24.

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18. Revision #5 released 8/15/24.

CTSU/A031102, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

CTSU/EA8171, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-GU002, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

CTSU/NRG-GU008, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node

Genitourinary Committee

Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin.
Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RTOG-0924, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/2022.

CTSU/EA8153, "Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial." Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

CTSU/AGCT1531, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

Translational Medicine

Chair: Dr. David McConkey

Co-Chair: Dr. Joshua Meeks

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta "Monty" Pal

Diverse Studies of Interest

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

CTSU/A031702, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

CTSU/EAY 131, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol Z1G reactivated: 2/23/22

CTSU/EA8134, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

Genitourinary Committee

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

Published/Accepted Manuscripts

S1011 Standard vs. Extended Lymphadenectomy for Muscle Invasive Bladder Cancer. Lerner S, Tangen C, Svatek R, Daneshmand S, Pohar K, Skinner E, Schuckman A, Sagalowsky A, Smith N, Kamat A, Kassouf mW, Plets M, Bangs R, Koppie T, Alva A, La Rosa F, Pal S, Kibel A, Canter D, Thompson I. N Engl J Med Oct 3;391(13):1206-1216, 2024.

<https://pubmed.ncbi.nlm.nih.gov/39589370/>

S1216 Circulating tumor cell (CTC) count is prognostic of overall survival in metastatic hormone sensitive prostate cancer (mHSPC). Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Jr., Hussain M, Quinn D, Dorff T, Thompson I, Jr, Agarwal N. JAMA Network Open Oct 1;7(10):e2437871, 2024. PMID39374015; PMC11581504.

<https://pubmed.ncbi.nlm.nih.gov/39374015/>

S1216 Correlation of body mass index with overall survival in patients with metastatic hormone-sensitive prostate cancer: Analysis of patient-level data from SWOG-1216 study. Swami U, Jo Y, Narang A, Plets M, Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara P, Thompson I, Hussain M, Dorff T, Lerner S, Agarwal N. Eur Urol Oncol. Nov 8;S2588-9311(24)00241-4, 2024. <https://pubmed.ncbi.nlm.nih.gov/39521639/>

S1314 DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial, Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, Choi W, Dinney C, Flaig T, Thompson I, Lerner S, McConkey D, Rosenberg J. JCO Precis Oncol. Nov;8:e2400287,2024.

<https://pubmed.ncbi.nlm.nih.gov/39565908/>

S1314 Predicting Clinical Outcomes in the S1314-Coxen Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression. Bai Z, Osman M, Brendel M, Tangen CM, Flaig TW, Thompson I, Plets M, Lucia S, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner SP, McConkey DJ, Faltas BM, Wang F. Accepted.

S1500 Final overall survival analysis of S1500: A randomized, phase II study comparing sunitinib to cabozantinib, crizotinib and savolitinib in advanced papillary renal cell carcinoma. Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tripathi A, Bjarnason G, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Balzer-Haas N, Lerner S, Pal S. Clin Oncol Nov 20;42(33):3911-3916.

<https://pubmed.ncbi.nlm.nih.gov/39255440/>

S1806 Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer. Singh P, Ballas L, Sonpavde G, Chen R, Bangs R, Bauman B, Nagar H, Delacroix S, Lerner S, Efstathiou J. Bladder Cancer Oct 23;10(3):199-213, 2024. <https://pubmed.ncbi.nlm.nih.gov/39493817/>

Submitted Manuscripts

E3805 Effect of Metformin and Body Mass Index on Quality of Life and Survival in the E3805 CHAARTED Trial. Jerrard D, Chen Y, Morgans A, Carducci M, Liu G, Eisenberger M, Wong Y-N, Hahn N, Bryce A, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R, Sweeney C. Submitted 2024.

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1802	S1806	S1931	S1937	S2011	S2200	S2210	S2312	A021804
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	7	-	1	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	1	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	3	8	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	8	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	1	6	-	1	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	1	1	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	11	4	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	5	-	3	-	-	6	-	-	-
Columbia University Minority Underserved NCORP	2	4	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	4	-	5	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	5	2	-	-	-	-	-	-	-
Desert Regional Medical Center	2	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	23	-	-	-	-	-	2	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	5	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	83	73	1	-	-	1	1	-	-
Hawaii Minority Underserved NCORP	-	4	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	11	8	1	-	4	3	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	27	4	-	1	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	4	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	20	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	18	-	2	-	-	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	9	6	1	2	-	-	-	-	-
Massachusetts Veterans Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	8	-	-	1	-	-	-	-	-
Mercy Medical Center - Des Moines	-	1	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	11	20	-	3	-	1	-	1	-
Montana Cancer Consortium NCORP	4	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas	11	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1802	S1806	S1931	S1937	S2011	S2200	S2210	S2312	A021804
Northwestern University LAPS	-	8	1	1	-	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	3	-	-	-	-	-	-	-
Oregon Health & Science University	-	1	1	-	-	1	-	-	1
Saint Joseph Hospital - Cancer Centers of Colorado	2	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	9	1	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	3	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	2	-	-	-	-	-
Tulane University School of Medicine	-	-	9	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	12	9	2	3	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	7	6	-	2	-	-	-	-	-
UC San Diego Moores Cancer Center	4	3	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	3	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	8	2	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	-	1	12	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	6	-	-	-	-	-	-
University of Arkansas for Medical Sciences	7	-	-	-	-	1	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	7	6	3	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	8	6	-	7	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	9	-	2	-	-	-	-	-
University of Kentucky/Markey Cancer Center	1	3	-	1	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	2	-	24	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	1	-	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	38	15	4	1	-	2	-	1	-
University of Rochester LAPS	25	-	3	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	12	-	4	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	86	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	-	1	2	-	3	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	3	2	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	8	6	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	2	-	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	12	6	-	-	-	-	-	-	-
Yale University- Yale Cancer Center LAPS	1	6	-	2	-	-	-	-	-
ALLIANCE	112	34	6	5	-	2	-	-	-
ECOG-ACRIN	97	44	14	8	1	4	-	-	-
NRG	108	136	12	2	-	3	-	-	-
Total	871	485	112	64	6	29	3	2	1

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A031701	A031702	A031704	A031801	A031803	A031902	A032001	A032101	A032103
Audie L Murphy VA Hospital	-	-	-	-	2	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	6	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	10	-	-	-	-	4	12	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	1	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	1	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	1	16	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	2	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	3	-	-	-	-	-	-
Henry Ford Hospital	-	2	6	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	66	-	-	-	-	-	-
Lahey Hospital & Medical Center	-	7	-	-	-	-	-	-	-
Loyola University Medical Center	-	1	2	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research & Information Center	-	-	-	-	-	1	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	1	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	1	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A031701	A031702	A031704	A031801	A031803	A031902	A032001	A032101	A032103
Northwestern University LAPS	-	-	2	-	-	-	-	1	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Oregon Health & Science University	-	5	5	-	-	-	-	-	1
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	1	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	10	-	3	7	5	-	2	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	1	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	5	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	-	1	12	-	-	-	-
University of Arkansas for Medical Sciences	-	-	2	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	7	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	11	-	-	-	-	2	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	1	7	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	12	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-	1
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	1
University of Rochester LAPS	-	3	9	-	-	-	1	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-	6	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	6	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	1	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	23	27	130	15	47	5	15	16	3

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	EA8134	EA8171	EA8185	EA8191	EA8192	EA8212
Audie L Murphy VA Hospital	-	49	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	20
Banner University Medical Center - Tucson	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	18
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	31	-	10
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	11	1	-	-	61
Hawaii Minority Underserved NCORP	-	2	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	2
Instituto Nacional De Cancerologia	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	3
Massachusetts Veterans Epidemiology Research & Information Center	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	3	-	6
Mercy Medical Center - Des Moines	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	2	-	-
NCORP of the Carolinas	-	-	-	-	-	1
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	EA8134	EA8171	EA8185	EA8191	EA8192	EA8212
Northwestern University LAPS	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Oregon Health & Science University	-	15	-	16	-	22
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	2
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	12	-	-	-	-	16
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	-	-	2	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	2	8
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	5	-	7
University of Rochester LAPS	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	13	-	2	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	6
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-
NRG	-	-	-	-	-	-
Total	13	91	1	60	4	182

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGGU008	NRGGU009	NRGGU010	NRGGU011	NRGGU012	NRGGU013
Audie L Murphy VA Hospital	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	2	-	-	-
Banner University Medical Center - Tucson	-	1	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	6	16	6	5	2	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	-	-	-
Lahey Hospital & Medical Center	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research & Information Center	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	1	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-
NCORP of the Carolinas	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-
Northwell Health NCORP	4	20	3	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGGU008	NRGGU009	NRGGU010	NRGGU011	NRGGU012	NRGGU013
Northwestern University LAPS	-	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-
Oregon Health & Science University	-	-	-	4	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	3	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	6	10	1	1	-
The West Clinic - Wolf River	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	2	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	2	-	1	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	14	10	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	2	8	7	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	1	-	-	-
University of Mississippi Medical Center	-	2	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	4	4	-	2	5
University of Rochester LAPS	-	-	4	-	-	-
University of Texas Health Science Center at San Antonio	-	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-
Virginia Mason Medical Center	-	4	3	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-
Western States Cancer Research NCORP	-	2	1	-	-	-
Wisconsin NCI Comm Oncology Research Program	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-
NRG	-	-	-	-	-	-
Total	14	80	61	11	6	5

